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Glioblastoma  multiforme  (GBM) is  the  most  common and deadly  tumor  of  the
central nervous system with a median overall survival of only 12-15 months from
time of diagnosis. Treatment consists of maximum safe resection surgery followed
by radio- and chemotherapy. Despite this heavy treatment tumor recurrence remains
ubiquitous  with  the  recurrent  tumors  being  more  aggressive  and  resistant  to
treatments,  underscoring  the need for  better  understanding  of  GBM biology and
improved treatment strategies for GBM patients. GBM tumors are highly different
from each  other  and  within  each  tumor  a  high location-dependent  heterogeneity
exists. On a cellular level, a tumor cell hierarchy is formed partially in resemblance
to that of a normal organ, with GBM stem cells (GSC) at the apex orchestrating the
tumor growth and composition. GSCs exploit pathways that are highly active during
normal  embryonal  development,  including  functions  such  as  cellular  migration,
asymmetric cell division and cellular differentiation. 
In  this  thesis,  the objective was  to  identify proteins  on GSCs to
direct  treatments  towards  these  hard-to-reach  cells.  We have  here  included  four
manuscripts  that  represent  the  fundament  of  our  research  to  achieve  this  goal.
Initially,  we  had  identified  cripto-1  as  a  potential  target  towards  GSCs  and
investigated its subcellular localization in an overexpression model to see where this
protein might be situated in order to evaluate whether it could be used as a target.
We showed that cripto-1 was mainly localized to the plasma membrane and was
highly  present  in  membrane-derived  filopodia  structures.  Next,  while  examining
cripto-1  in  wildtype  (non-overexpressed)  GBM  cells,  we  saw  some  unexpected
binding of the cripto-1 antibodies used. This led to an evaluation of four different
cripto-1 antibodies,  reporting different  results from each  of these antibodies,  and
thus a discontinuation of cripto-1 research was decided.
In order to better identify new and relevant targets, we needed more
translatable GBM cellular models for both  in vitro  and  in vivo studies.  Here,  we
characterized  a  patient-derived  tumorsphere  model  that  showed  intercellular
heterogeneity both in vitro and in vivo and could be used for therapeutic assessment
in vitro. Next, we expanded on this model and set up a larger in vivo study where we
examined  how  conventional  GBM  treatments  (radiotherapy  and  temozolomide)
affected  the  cellular  composition  of  the  GBM tumors.  Through  multicolor  flow
cytometry and FlowSOM clustering analysis,  we showed that  an upregulation of
CD44 was seen in all treatment groups compared to the untreated group. This could
indicate that CD44 could become a target for future directed treatments, however,
we still  have a long road ahead of us. In the overall discussion presented in this
thesis, I cover some contextual topics that include modeling of GBM tumors and
targeting GSCs.  I  believe  that  the results  presented  here have contributed to the
overall understanding of cripto-1 protein in GBM cells and the challenges that come
with  it.  Our  investigation  of  GBM  cell  plasticity  in  response  to  conventional
treatment has paved a new way of studying such phenomenon with flow cytometry
and cluster analyses which could potentially be adapted to clinical settings.
9
META DATA TITLE HERE
DANSK RESUME
Glioblastoma multiforme (GBM) er den mest almindelige og dødbringende tumor i
centralnervesystemet med en gennemsnitlig overlevelse på kun 12-15 måneder fra
diagnose. Behandlingen består af kirurgi efterfulgt af stråle- og kemoterapi. På trods
af  den  hårde  behandling  sker  der  i  alle  tilfælde  genvækst  af  tumoren,  idet  de
tilbagevendende tumorceller er mere aggressive og resistente over for behandling,
hvilket  understreger  behovet  for  bedre  forståelse  af  GBM  biologi  og  bedre
behandlingsstrategier  for  GBM patienter.  GBM tumorer  er  meget  forskellige  fra
hinanden,  og  i  hver  tumor  findes  en  høj  lokaliserings-afhængig  cellulær
heterogenitet.  På  celleniveau  dannes  et  tumorcellehierarki  som på  mange  måder
ligner det som ses i et normalt organ, med GBM stamceller (GSC) i toppen som
orkestrerer  tumorvækst  og  sammensætning  af  celler.  GSC’er  gør  brug  af
signaleringsveje der oftest ses  aktive under normal embryonal udvikling, hvilket
inkluderer funktioner såsom cellulær migration, asymmetrisk celledeling og cellulær
differentiering.
Formålet  med  denne  afhandling  var  at  identificere  proteiner  på
GSC’er for at målrette behandling mod disse resistente celler. Vi har her inkluderet
fire manuskripter, som danner grundlaget for vores forskning for at nå dette mål.
Oprindeligt  havde vi  identificeret  cripto-1 som et  potentielt  mål mod GSC'er  og
undersøgt dets subcellulære lokalisering i en overekspressionsmodel. Formålet var at
se hvor dette protein er placeret for at evaluere, om det kunne bruges som et mål i
behandling. Vi fandt at cripto-1 hovedsageligt var lokaliseret til plasmamembranen
og  var  meget  til  stede  i  cellemembran-deriverede  filopodia-strukturer.  Dernæst,
mens vi undersøgte cripto-1 i vildtype (ikke-overudtrykte) GBM celler, så vi uventet
binding  af  de  anvendte  cripto-1-antistoffer.  Dette  førte  til  en  evaluering  af  fire
forskellige cripto-1-antistoffer der alle viste forskellige resultater, hvilket førte til en
afvikling af vores cripto-1-forskning.
For bedre at kunne identificere nye og relevante mål havde vi brug
for bedre cellulære GBM modeller til både  in vitro og  in vivo eksperimenter. Her
karakteriserede  vi  en  patient-afledt  tumorsphere  model,  der  viste  intercellulær
heterogenitet både in vitro og in vivo, og kunne bruges til evaluering af behandling
in  vitro.  Dernæst  udvidede  vi  på  denne  model  og  udførte  et  større  in  vivo
eksperiment,  hvor  vi  undersøgte,  hvordan  konventionelle  GBM  behandlinger
(strålebehandling  og  temozolomid)  påvirkede  den  cellulære  sammensætning  af
GBM tumorer. Gennem avanceret flowcytometri og FlowSOM-analyse viste vi, at
der blev set en opregulering af CD44 i alle behandlingsgrupper sammenlignet med
den  ubehandlede  gruppe.  Dette  kan  indikere,  at  CD44  kan  blive  et  mål  for
fremtidige  målrettede  behandlinger.  I  den  samlede  diskussion  der  præsenteres  i
denne afhandling, dækker jeg nogle kontekstuelle emner, der inkluderer modellering
af GBM tumorer og målretning mod GSC'er. Samlet set har vi med disse resultater
bidraget til en udvidet forståelse af cripto-1 proteinet i GBM celler samt vist en ny
måde at  lave en detaljeret  undersøgelse af behandlingsresistente tumorceller  med
flow cytometry som potentielt kan implementeres i klinikken.
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PREFACE
The work presented in this PhD thesis is based on research mainly carried out at
Aalborg  University  as  a  part  of  Laboratory  of  Cancer  Biology.  The  research
conducted  is  presented  in  four  separate  manuscripts.  Parts  of  the  experiments
performed in Manuscript III and all experiments in Manuscript IV were done during
my two research stays  in Copenhagen.  The first  stay was from August  2017 to
December  2017,  and  the second was  from September  2018 to December  2018.
During these stays I was a part of Center for Nanomedicine and Theranostics at the
Technical  University of Denmark (DTU) lead by Professor Thomas L. Andresen
who has a tight collaboration with Cluster for Molecular Imaging at University of
Copenhagen  lead  by  Professor  Andreas  Kjær.  All  in  vivo  experiments  were
performed in their animal facilities at the Panum Institute. 
The thesis has been submitted as  a  compilation thesis  (collection of  articles)  in
concordance  with  the  requirements  set  by  the  Doctoral  School  in  Medicine,
Biomedical Science and Technology at Aalborg University. The thesis consists of a
broad  introduction  to  the  field  (Chapter  1)  followed  by  the  thesis  objectives
(Chapter  2).  Chapter  3  consists  of  a  brief  summary  of  the  findings  from each
manuscript  presented  as  extended  unstructured  abstracts.  Chapter  4  presents  a
discussion  of  key  findings  from  the  manuscripts  and  a  relation  of  these  to
methodological  or  conceptual  issues.  Lastly,  the  thesis  ends  with  concluding
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CHAPTER 1. INTRODUCTION 
Glioblastoma  Multiforme  (GBM)  is  the  most  frequent  malignant  tumor  of  the
central nervous system (CNS), representing 46.6 % of all malignant CNS tumors in
the United States in the years  2009 – 2013. The population incidence in United
States is 3.2 per 100.000 and median age of diagnosis is 64 years. Overall survival
rates are poor with a median survival of 15 months from diagnosis.  [1] GBM is
classified as primary (or  de novo) with a short clinical history or secondary which
arises from lower grade astrocytomas [2]. Three transcriptomic profiles have further
subdivided GBM into classical, proneural and mesenchymal subtypes  [3]. Current
treatment consists of maximum safe resection surgery followed by radiotherapy plus
concomitant  and adjuvant  chemotherapy with the alkylating agent  temozolomide
(TMZ)  [4]. In spite of such heavy treatment tumor recurrence remains inevitable,
often accompanied by several  satellite  tumors forming at  distant  locations in the
brain  (Figure  1.1)  [4,5].  Extensive  research  efforts  and  clinical  trials  have  been
conducted  in  order  to  improve  current  treatment  outcomes,  however,  most  have
failed.  A  positive  prognostic  indicator  for  TMZ  treatment  response  is  the
hypermethylation,  and  thus  inactivation,  of  the  O-6-methylguanine-DNA
methyltransferase (MGMT) promoter [6]. A recent phase 3 clinical trial showed that
the combination of the alkylating nitrosurea lomustine combined with TMZ might
be superior to TMZ alone in GBM patients with hypermethylated MGMT promoter
[7].  Another  therapeutic  agent  that  seemed  promising  was  the  anti-VEGF-A
immunotherapy  bevacizumab.  However,  bevacizumab  did  not  show  significant
results and induced adverse effects in some GBM patients [8,9]. Since bevacizumab
showed  effects  in  few  patients,  it  has  still  been  FDA  approved  as  a  last-line
treatment, highlighting the desperate need for improvement [10]. 
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Figure 1.1. Potential situation before and after treatments for GBM, showing migration, 
satellite tumor formation and recurrence of primary tumor after surgery.
1.1. GLIOBLASTOMA STEM-LIKE CELLS: THE WHAT, WHERE 
AND HOW
GBM tumors are highly heterogeneous consisting of various tumor cells, healthy
tumor-associated  cells,  different  immune  cells,  and  a  small  fraction  of  highly
malignant  GBM  stem-like  cells  (GSCs).  GSCs  were  initially  discovered  in  the
beginning of the 2000’s where neural stem-like cells were found in cortical gliomas
19
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and GBM  [11,12].  Generally,  GSCs are defined as highly malignant tumor cells
with stem cell  properties  such as  asymmetric  cell  division,  unlimited replication
capacity,  capable of differentiation and able of tumor formation  [13]. These cells
have been implicated in processes such as invasion, angiogenesis, immune evasion
and  therapeutic  resistance  [13] (Figure  1.2).  Several  protein  markers  have  been
proposed to identify GSCs such as CD133, Nestin, Oct-4, Sox2 and CD44, most of
which have previously been associated with neural stem cells and radial glial cells
[14–17]. Within a single GBM tumor, several subtypes of non-stem cells and GSC
subtypes have been identified adding to the immense complexity of the composition
of GBM [18]. 
Figure 1.2. Overview of key functions orchestrated by GSCs in glioblastoma pathogenesis 
and progression.
1.1.1. STEM-LIKE CELLS AT THE APEX OF TUMOR CELL HIERARCHY
The event of tumor formation is not well elucidated, but two theories currently exist;
the  stochastic  (or  clonal  evolution)  theory  and  the  hierarchical  cancer  stem cell
theory. The stochastic theory proposes a clonal selection of tumor-initiating cells
that in the end are quite similar (stemness-wise) or homogenous and can all form a
tumor, following the ‘survival of the fittest’ principle. The cancer stem cell theory
proposes  that  tumor  formation is  more  like the  process  of  organogenesis  during
embryonal  development  in  which  cancer  stem cells  are  responsible  for  cellular
differentiation,  creating  a  highly  heterogeneous  tumor  (Figure  1.2).  Since  most
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tumors to date have shown intratumoral cellular heterogeneity including cancer stem
cell populations, the cancer stem cell theory has over the past decade gained more
support  than  the  stochastic  theory.  In  GBM,  much  evidence  exists  on  the
intercellular  heterogeneity  in  which  GSCs  have  been  proposed  to  dictate  the
formation, composition and progression of GBM tumors [13,19,20]. 
1.1.2. THE GSC NICHES
The thought and fascination of the heterogenic development of gliomas is not new.
In 1938, Hans Scherer compiled his work on glioma morphology from 100 patient
autopsies  and described  tumor cells  in  white  matter  tracts  and clustering around
vasculature in the tumor periphery [21]. Today, we know much more of which cell
types occupy the different spaces or niches. The GSCs have been found residing in
specific niches, such as the perivascular niche, perinecrotic or hypoxic niche and the
less elucidated invasive niche, as illustrated in Figure 1.3  [20]. In the perivascular
niche, GSCs have been found to interact  with surrounding cells to promote self-
growth and cell invasion [22,23], but it has long been debated which type of blood
vessel  the  GSCs prefer  to  harbor.  Recently,  it  was  suggested  that  GSCs cluster
around arterioles due to the notion of arterioles not allowing oxygen exchange with
surrounding tissue, thus creating a hypoxic state  [24]. This hypoxic periarteriolar
niche has been hypothesized of being the main type of perivascular GSC niche and
has been rationalized due to its high similarity to hematopoietic stem cell niches in
the bone marrow  [24–26].  Hypoxia is  a  key inducer  of  stemness  in  all  types  of
cancer, including GBM  [27,28]. The perinecrotic niche is also called the hypoxic
niche and has been shown to be enriched in GSCs. Maintenance of GSCs in the
perinecrotic  niche  has  been  attributed  to  hypoxia-inducible  factor  2α  (HIF-2α)
through  activation  of  CD44  [29,30].  CD44-induced  HIF-2α  activation  was  also
shown to  induce  a  pseudo-hypoxic  phenotype in  perivascular  GSCs  [29].  Other
members  of  the  HIF  family also regulate  the  GSC stemness  through embryonal
pathways such as Notch-Jagged and TGFβ [28,31]. A less defined enrichment site of
GSCs is the invasive niche, most likely due to difficulties in studying the invasive
cells in GBM patients [20]. It is widely shown that invasive cells in GBM possess
stem-like  characteristics,  and  several  motility-associated  pathways  have  been
discovered as key in GSC invasion, including Ephrin, TGF-β and Integrins resulting
in Rho and Ras-mediated activation of NF-kβ, JAK/STAT3, IRF3 and PRC2 [32].
Also in GBM invasion, hypoxia has been shown to induce an invasive stem-like
phenotype promoting mesenchymal traits [31,33]. 
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Figure 1.3. Illustration of the proposed GSC niches; the perinecrotic, perivascular and 
invasive niche.
GSCs in brain tissue invasion
GBM  tumor  formation  and  progression  depends  on  several  key  mechanisms,
including invasion,  angiogenesis  and  immunosuppression  in  which  GSCs play  a
crucial role. GSCs mainly utilize two defined routes of invasion; via perivascular
spaces  and  white  matter  tracts.  In  perivascular  invasion,  GSCs  are  attracted  by
bradykinin  secreted  by  endothelial  cells  and  have  been  shown  to  use  different
membrane  proteins  for  invasion,  such  as  CXCL12-CXCR4  and  Notch-Jagged
interactions  [34–36].  GSCs  in  perivascular  invasion  have  been  characterized  as
Nestin+CD133+  [23],  indicating  a  neural  stem/progenitor  phenotype,  whereas
another study showed specific perivascular invasion from Olig2+ GSCs via Wnt7
signaling, indicative of an oligodendrocyte  progenitor  phenotype  [37].  The study
further  displayed that  Olig2+ GSCs invaded as single cells in contrast  to Olig2-
which demonstrated collective cell invasion  [37]. In white matter-based invasion,
similar mechanisms of GSC-substrate interactions have been found to be applied,
i.e.  via  Notch1-Jagged1  mediated  invasion  [38].  Myelinated  fibers  contain  the
membrane protein Nogo-A which inhibits cell migration via inactivation of RhoA
signaling, however, GSCs have found a way to overcome this challenge [39]. Upon
encountering  Nogo-A,  GSCs  employ  a  decoy  mechanism  by  rapid  secretion  of
SPARC which binds Nogo-A and blocks its inhibitory effects on RhoA signaling
[39].  Wang  et  al.  characterize  the  white  matter-invading  GSCs  as  mostly
CD133+Notch1+ and CD44-  [38].  One study has shown that  distinct  anatomical
regions  such  as  the  hippocampus  have  been  spared  for  GBM invasion,  perhaps
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indicating  a  preference  for  certain  extracellular  matrix  (ECM)/substrate
compositions [40].
In order to penetrate the healthy brain parenchyma, the GSCs also
interact  with  and  degrade  healthy  ECM  via  different  integrins,  matrix
metalloproteinases (MMP) and a disintegrin and metalloproteinases (ADAM) [41–
43]. For example, FoxM1-controlled expression of ADAM17 activated the EGFR
pathways which resulted in a mesenchymal transition and increased migration in
GBM cells [44]. Tenascin-C induced ADAM9 activation was also shown to induce
invasion in GBM cells, and silencing ADAM9 resulted in less ECM adhesion and
cancer cell migration by interference of β1-integrin activity at the plasma membrane
[45,46]. The mesenchymal features (i.e. high CD44 expression) often adopted by
GBM cells prior to invasion indicates that the invasive cells often possess stem-like
characteristics, although proneural GSCs (Olig2+) have also been shown to venture
down an invasive path [37,47].
The neovascularization cascade
GBM invasion often occurs in perivascular spaces of healthy blood vessels which
can be considered the first step of the tumor neovascularization cascade that occurs
in GBM, namely vascular co-option. Vascular co-option is defined as the process of
tumor cells surrounding healthy blood vessels, leeching off the oxygen and nutrients
[48]. Inevitably, the tumor cells start expanding rapidly in the area around the newly
adopted blood vessel generating a dense tumor core  [49,50]. With the tumor cell
expansion follows endothelial cell apoptosis and blood vessel disintegration, which
leads to hypoxia switching on the angiogenic ‘switch’ in order to form new blood
vessels  [50,51]. At this point, several  different mechanisms of neovascularization
have been identified, including angiogenesis, vasculogenesis, vascular mimicry and
glioma-endothelial  cell  transdifferentiation  [49].  The  most  widely  studied  is  the
process  of  angiogenesis  which,  similar  to  vasculogenesis,  is  triggered  by  local
hypoxia which causes  GSC secretion of  VEGF and SDF-1α and upregulation of
endothelial CXCR4 [52,53]. In addition to this, GSCs have been shown to generate
tumor-derived pericytes via TGF-β1 to support the functionality of newly formed
blood vessels [54]. Upregulation of endothelial CXCR4 attracts CXCL12 on GSCs
and thus also promotes invasion [55].
Immuno-manipulation
In order to avoid death by hand of the immune system, GBM cells have acquired the
ability to recruit immune cells, such as macrophages and T cells, and manipulate
them into  an  immunosuppressive  phenotype via  upregulation  of  several  proteins
such as TGF-β, IL-6, aryl  hydrocarbon receptor,  CD39 and PD-L1  [56–58].  Not
only peripheral immune cells are affected, but also reactive astrocytes and microglia
contribute  to  the  immunosuppressive  environment  in  GBM  and  thus  tumor
progression [59]. GBM subtype specific differences in the immune landscape exists
with  CD68+  microglia  and  CD163+  BM-derived  macrophages  being  the  most
prevalent in all subtypes to different extents [60]. Mesenchymal GBM displayed the
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highest infiltration of microglia, macrophages and lymphocytes  [60]. Responsible
for the immune-manipulation, GSCs have been shown to play a key role in attracting
immune cells and shaping the immunosuppressive landscape of GBM [61–64]. 
Several  of  the  pathways  mentioned  here  overlap  with  the  different  functions
described. For example, ADAM17 has been shown to be involved in CD44-HIF-2α
signaling,  regulating  both  matrix  modulation  and  perivascular  hypoxia  response
[29].  Furthermore,  Notch1  was  involved  in  both  perivascular  and  white  matter
invasion, but was also shown to induce an angiogenic phenotype by stimulation of
pericyte-like differentiation and upregulation of several angiogenic factors such as
heparin  binding EGF and VCAM1  [35,38,65]. These  examples  demonstrate  that
both  pathways  and  functions  dynamically  overlap  in  order  to  support  GBM
progression.
1.1.3. A PLASTIC UNIVERSE: ACQUIRED RESISTANCE
In addition to the intercellular heterogeneity another layer of complexity is added to
the tumor equation with many of the cells present in tumors being highly dynamic or
plastic. Plasticity is the ability of a cell to adapt to external factors such as changes
in  the  extracellular  environment  surrounding  the  cell  or  hostile  factors  such  as
chemotherapy and irradiation. In cancer, this phenomenon has been suggested as a
mechanism for cancer cells to overcome treatments and has been linked to cancer
stem-like cells  [66,67]. This has been illustrated multiple times in GBM where the
recurrent tumor displays a much more aggressive and treatment resistant phenotype
than the primary tumor  [68]. GBM tumors initially characterized as proneural had
shifted  towards  a  mesenchymal  phenotype  after  recurrence,  rendering  it  more
resistant  to  treatment  [68,69].  Also  in  the  invasive  edge  (or  niche),  GSCs
transitioned  from  a  CD133+  proneural  signature  to  a  CD109+  mesenchymal
signature in response to radiotherapy  [70]. On a more macroscopic level,  GBM
cells were shown to rapidly increase their formation of tumor microtubes in response
to  standard  GBM  treatment  modalities  [71,72].  The  GBM  cells  where  able  to
stabilize their levels of intracellular calcium by increased calcium communication
with  surrounding  cells  mediated  through  Connexin  43  in  interconnected  tumor
microtubes, thus evading cell death [72]. 
1.2. TUMOR MORPHOGENESIS: DEVELOPMENTAL GENES RE-
EXPRESSED 
Cellular plasticity is also key during embryonal development where, unlike cancer,
coordinated  gradients  of  different  growth  factors  known as  morphogens  provide
concentration-dependent cellular cues to shape the architecture of organisms. The
process of organismal development is called morphogenesis and has for centuries to
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this day fascinated researchers  [73]. Alan Turing was mostly renown for breaking
the enigma code and his contribution to computer science, however, after the second
world war Turing found an interest in mathematical biology. In 1952, he published a
paper  on  the  chemical  basis  of  morphogenesis,  in  which  he  presented  a
mathematical model of chemical diffusion of morphogens ultimately suggesting a
chemical  gradient that allows for anatomical  differentiation  [74]. Since then, this
theory has been verified experimentally  and expanded upon, identifying multiple
morphogens in the process and cellular structures responsible for their distribution
[75]. Members of the TGFβ family were the first extracellular morphogens to be
described  in  Drosophila  and  Xenopus studies  [75].  For  example,  the  bone
morphogenic  protein  (BMP) homolog Decapentaplegic  was  found to  pattern the
dorsal-ventral  axis in  Drosophila embryos  [76].  By injecting RNA transcripts  of
Decapentaplegic into young embryos, the increased concentration decreased ventral
ectoderm development and increased development of the most dorsal tissues  [76].
Several cellular mechanisms known to occur during morphogenesis have also been
observed in tumors, such as collective cell migration  [77]. Countless morphogens
have been discovered in various tumor settings as well such as TGFβ, Nodal, Wnt
proteins  and  hedgehog,  indicating  that  tumors  utilize  morphogens  for  their
development and growth, much like healthy tissue [78–80].
1.2.1.  CELLULAR PROTRUSIONS CONVEYING MORPHOGEN 
DISTRIBUTION AND CELLULAR MIGRATION
Cellular  membrane  protrusions  come in  many shapes  and  sizes  and  exert  many
different functions such as sensing the cell’s surroundings, cell migration and cell
communication  [81,82]. The largest of these structures are lamellipodia which are
large F-actin rich protrusions at the cell’s leading edge, often ruffled in appearance
[81,83,84]. In the smaller end, different types of filopodia-like structures have been
identified  including  tunneling nanotubes,  retraction  fibers,  tumor  microtubes  and
specialized filopodia/cytonemes, all of which are also rich in F-actin [72,85–87]. In
general,  filopodia are small finger-like protrusions of the plasma membrane often
extending  from  lamellipodia  at  a  cell’s  leading  edge.  Filopodia  are  thought  to
participate  in  sensing  environmental  cues  and  in  orchestrating  directional  cell
migration  [88].  Tunneling  nanotubes  are  thin,  open-ended  tubes  between  cells
allowing for free transport of molecules between them, whereas tumor microtubes
are similar but with closed ends [89]. In tumor microtubes, the transfer of molecules
instead occurs via gap junctions such as complexes of connexin-43 [72]. From the
trailing edge, retraction fibers are thin filopodia-like structures that extend rearward
and are left  behind the cell  as it  moves,  and has been shown to be essential for
detachment  from  adhesive  substrates  [90–93].  Beneath  the  cell,  short  actin-rich
protrusions called puncta or podosomes (or invadopodia in malignant cells) mediate
adhesion and matrix degradation during cell migration and are typically identified
by  the  co-localization  of  F-actin  and  cortactin  [94,95].  The  cellular  membrane
protrusions are illustrated in Figure 1.4.
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The  mechanisms  by  which  morphogenic  gradients  are  formed
include  free  diffusion,  cellular  transcytosis  and  via  cellular  protrusions  such  as
filopodia  [86]. Filopodia structures involved in morphogen transport are typically
referred to as specialized filopodia, cytonemes or just filopodia, and their structure
and  composition  is  highly  similar  to  filopodia  discovered  in  other  contexts
[75,86,87].  Filopodia-based  signaling  is  highly  active  during  embryogenesis,
transporting Wnt proteins to create concentration gradients during tissue patterning
(illustrated  in  Figure  1.5)  [96–99].  In  order  to  form  and  regenerate  tissue,  cell
migration  is  most  often  required,  including  both  physiological  and  malignant
processes  such  as  embryogenesis  and  carcinogenesis.  A  cell  can  sense  its
environmental surroundings, and the subsequent trigger of migration can either be in
response to bound (haptotaxis), soluble (chemotaxis) or mechanical (durotaxis) cues
[100].  Filopodia have  been  shown to be implicated  in  all  of  these  processes;  in
haptotaxis  through  ECM  adhesion  via  integrins  present  at  the  filopodia  tip,
chemotaxis through morphogen secretion inducing migration in surrounding cells,
and durotaxis by probing ECM topography and rigidity [101]. 
Figure  1.4. Overview of  the different  cellular  membrane  protrusions  introduced.  Arrows
indicate the direction of cell movement.
1.2.2. MORPHOGENS IN GBM
Cellular membrane protrusions, such as the ones mentioned above, are thought to be
present in all cell types in various forms and degrees, including GBM cells [89,102].
Although morphogen transport in membrane protrusions have been scarcely studied
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in  GBM,  several  morphogens  have  been  found  to  play  key  roles  in  GBM
pathogenesis. The morphogen Wnt5a was shown to be a key driver of the invasive
GSCs and by inhibiting Wnt5a expression cell invasion decreased and host survival
increased  [103,104].  Wnt  proteins  were  also responsible for  GBM cell-microglia
interaction and activation, ultimately resulting in GBM progression by promoting
immunosuppression and cell invasion [105]. During GBM tumorigenesis, the TGFβ-
related  protein  Nodal  was  observed  to  be  highly  expressed  in  GSCs  and
downregulated  in  differentiated  GBM cells  [106].  In  patient-derived  GBM cells,
dysregulation  of  the Wnt  pathway was  shown to be caused  by the lack  of  Wnt
pathway inhibition by secreted frizzled-related protein 1 (SFRP1) due to epigenetic
silencing of the SFRP1 promoter  [107]. Subsequently, treatment with recombinant
SFRP1 resulted in decreased tumorsphere formation [107]. TGFβ was also shown to
induce  and  maintain  GSC self-renewal  through induction of  leukemia  inhibitory
factor  expression  in  patient-derived  GBM  cells  [108].  Sonic  hedgehog  (Shh),
another  important  morphogen in mammalian development,  was shown to initiate
tumor formation in neural stem cells when dysregulated in a zebrafish model [109].
As previously mentioned, hypoxia-induced stemness is highly involved in several of
the  GSC  niches  and  functions  that  drive  GBM  progression.  During  embryonal
development, hypoxia also plays a crucial role in regulating cellular differentiation
and growth through the same genes as in GBM, such as members of the HIF family
[110,111].  These  examples  clearly  underscore  a  close  resemblance  between
pathways active during morphogenesis and GBM formation/progression. Therefore,
targeting morphogen-expressing GBM cells could be a way to enhance treatment
efficiency.
Figure 1.5. Suggested mechanism of morphogen and oxygen distribution that maintains 
stemness and induces cellular differentiation in a concentration-dependent manner in GBM.
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1.3. TARGETING THE PLASTIC CELLS IN GBM
Treatment of GBM tumors has proven a monumental task evident by the fact that
the  disease  still  is  uncurable  and  only  modest  improvements  have  been  seen  in
patient overall survival. As outlined in this introduction, one of the major obstacles
of  effectively  treating  GBM  tumors  is  the  ability  of  GSCs  to  adapt  to  hostile
environments.  Thus,  targeting  the  plastic  GSCs  could  be  key  for  future  GBM
treatments.
1.3.1. CRIPTO-1 AS A POTENTIAL TARGET IN GBM
Cripto-1 is a glycosylphosphatidylinositol (GPI)-anchored surface protein involved
in the morphogenic signaling pathways Wnt/β-catenin and TGFβ/Smad (pathways
summarized in Figure 6) [112–114]. Cripto-1 is a member of the EGF-CFC domain
family of  proteins which all  contain the evolutionarily  conserved  EGF and CFC
domains [112]. Cripto-1 acts as a co-receptor for several morphogens such as Nodal
and  Notch,  and  thus  participate  in  embryogenesis  [115].  During  embryonal
development,  Cripto-1  was  crucial  for  tissue  polarization  during  gastrulation
responsible  for  correct  orientation  of  the  anterior-posterior  axis  [116,117].
Moreover,  Cripto-1  was  involved  in  the  generation  of  the  notochordal  plate,
prechordal mesoderm and foregut endoderm [118]. In the adult, Cripto-1 expression
has been proposed to be turned off or limited to small stem cell populations, only to
see it highly re-expressed in several types of cancer  [119,120]. Cripto-1 has been
associated with processes that relate to its function during embryonal development
such as cell invasion or migration, epithelial-mesenchymal transition and treatment
resistance,  thus  seeming  important  in  tumor  cell  plasticity  [121–124].  In  GBM,
Cripto-1 has not been extensively studied, but has been found in sera and tissue from
GBM patients and Cripto-1 expression correlated with shorter survival  [125,126].
Studies investigating Cripto-1 overexpressing U87MG cells showed that the cells
increased expression of stemness markers Nanog, Oct4, Sox2 and CD44, and that
the cells became more proliferative, invasive and angiogenic in vitro [127,128]. In
support of this, overexpression of Nodal increased Cripto-1 expression in vitro and
increased glioma progression in vivo [129].  Due to its extensive presence shown in
stem-like cells in other cancers, several papers have suggested Cripto-1 as a target
for therapy [130–132]. However, Cripto-1 knockout studies have shown that it has
detrimental impact on mouse embryos, where no Cripto-1 knockout mice were born
due to aberrant morphogenesis before and during gastrulation [117,133]. The effects
of Cripto-1 inhibition in healthy adults has not, to my knowledge, been investigated
and  thus  side  effects  from  targeting  Cripto-1,  if  functionally  inhibited  by  the
treatment, need to be examined. Since GBM has no cure and the median survival is
so low, looking into targeting Cripto-1 might still be relevant. 
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Figure 1.6. Summary of Cripto-1 interaction partners, pathways and functions.
1.3.2. CD44 IN GBM
CD44  is  associated  with  stem  cells  in  various  healthy  and  malignant  tissue,
including  GBM  [134].  CD44  is  a  transmembrane  glycoprotein  consisting  of  an
extracellular domain, transmembrane domain and a cytoplasmic tail, and comes in
several different splice variants which have been shown to be involved in different
functions [135–138]. Some studies suggest that a soluble form of CD44 exists that is
functional and can be used as a plasma biomarker  [138–140]. The main ligand of
CD44 is hyaluronan (or hyaluronic acid, HA) which is a major constituent of ECM,
and  further  upregulated  during  processes  where  cell  migration  is  key  such  as
embryonal development and inflammation  [141]. In low-grade glioma (LGG) and
GBM patients, CD44 expression has been shown to be increased and linked with a
poor  overall  survival  [142–144].  CD44 has  been  linked  to  cellular  resistance  to
treatments, for example by upregulating multidrug transporters [145,146]. Although
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less  investigated  in  GBM,  CD44  expression  has  been  found  to  contribute  to
treatment resistance [16,22,147,148]. Depletion of CD44 was shown to cease GBM
tumor growth in vivo and sensitize the cells to cytotoxic treatment by inhibition of
the  Hippo  signaling  pathway  [147].  Mesenchymal  GBM  was  shown  to  be
CD44highOLIG2low and  was  highly  resistant  to  radiation  treatment  compared  to
proneural GBM which was defined as CD44lowOLIGhigh [16]. Another study showed
that  CD44+ GSCs  residing  in  the  perivascular  niche  were  radioresistant  due  to
activation  of  CD44  via  Osteopontin  [22].  This  indicates  that  combining  CD44
inhibition with standard GBM treatment could make it more effective, however, side
effects related to targeting such a common receptor need to be evaluated carefully.
1.4. CELLULAR MODELS OF GBM
The  past  decades  have  demonstrated  significant  technological  advances  within
fundamental  biological  research allowing scientists to analyze GBM tumors with
ever-increasing  resolution.  The  resulting  new  knowledge  about  GBM  tumors
brought with it a realization concerning the lack of clinical reproducibility of cellular
models of GBM, creating a shift  from ‘generic’  GBM cell lines towards patient-
derived cells. 
1.4.1. HUMAN PATIENT-DERIVED GBM CELLS
The most commonly used GBM cell lines are U87MG and U251, both isolated from
patients in the late 1960’s [149,150]. The cell lines were selected by adherence to a
substrate  using  serum-rich  medium.  Three  decades  later,  the  fundamental
identification  and  purification  of  brain  tumor  stem-like  cells  using  CD133  as  a
marker solidified the cancer stem cell hypothesis in solid brain tumors  [151,152].
These  studies  employed  a  protocol  for  neural  stem  cell  isolation  and  culture
conditions  on  dissociated  brain  tumor  material  resulting  in  multicellular  non-
adherent tumorsphere cultures. Such culture media formulations are still used today
with slight differences in the supplements added  [153,154]. When isolating GSCs,
some laboratories have sorted for CD133+ cells in order to further enrich for stem
cell properties, whereas most do a ‘bulk’ isolation without sorting to maintain the
original tumor cellular heterogeneity [153,155,156].
Patient-derived GBM cells (PDGCs) are rarely (if ever) cultured under conventional
culture conditions with the addition of serum, but rather maintained in GSC culture
medium  with  added  growth  factors  and  supplements  that  support  stemness  as
tumorspheres. In recent years, more research has been put into growing PDGCs as
organoids in order to preserve intercellular heterogeneity and further push the limits
of the complexity of cell cultures in vitro.  Here,  single GBM cells directly from
dissociated tissue or tumorspheres are embedded in a relevant ECM (matrigel, for
example) in GSC medium on an orbital shaker in a humidified incubator [157,158].
Hubert et al. showed that mouse xenografts using patient-derived tumor organoids
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reflected  the  patient  tumor  with  a  diffuse  infiltrative  growth  pattern  whereas
tumorspheres  isolated  from  the  same  patients  presented  as  encapsulated  tumors
when xenografted  [157].  Taken a step  further,  Linkous et  al.  generated  cerebral
organoids from human embryonic stem cells and added to this patient-derived GSCs
to  more  accurately  recreate  gliomagenesis  with  host-tumor  interactions,  even
demonstrating  the  role  of  tumor  microtubes  in  GSC invasion  [159].  Generation
GBM organoids  is  a  time-consuming process  taking up to  12 months for  single
GBM organoids to fully mature, but still show more clinical relevance both in vitro
and in vivo compared to other GBM culture methods [157,158].
1.4.2. SYNGENEIC MURINE GBM MODELS
As described  earlier,  the host  immune system plays an essential  role in shaping
GBM pathogenesis and progression. One major pitfall of patient-derived xenograft
models  is  the use of  immunocompromised animals  to facilitate  xenografting.  To
include  an  intact  immune  system  in  the  study  of  GBM  biology  and
immunotherapies,  mainly  two  methods  have  been  used  to  generate  syngeneic
models; genetically modified or chemically induced. Genetically modified models
include genetic engineering and transduction with viral vectors. Viral vectors have
been  used  to  cause  gain-of-function  of  oncogenes  such  as  PDGFB,  EGFRvIII,
activated p21-RAS and activated AKT  [160]. Genetically engineered models have
also been used to activate EGFRvIII, EGFR, p21-RAS, PI3K, CDK4 and MDM2,
and loss-of-function of PTEN, TP53, CDKN2A and RB in different combinations
[160–163].
The most widely used syngeneic GBM models are the chemically-induced models
GL261  and  GL26  which  have  allowed  for  the  preclinical  studies  of
immunotherapies  in  GBM  [164–166].  These  cell  lines  are  typically  cultured  as
adherent  monolayers  with  serum  added  to  the  culture  medium,  but  GL261  has
previously  been  cultured  in  stem-like  conditions  which  induced  a  CD133+  cell
subpopulation [167]. GL261 cells, which have been more extensively characterized
than GL26, have been shown to replicate some macroscopic features often seen in
human GBM such as central necrosis and neovascularization [50]. However, most of
the characterization of these cells has focused on the immune aspects [165,168].
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The  invasive  nature  and  inherent  and  acquired  therapeutic  resistance  of  GBM
tumors calls for better understanding of GSCs to enable the development of novel
treatments. The objectives of this thesis were to identify relevant therapeutic targets
through an improved cellular and molecular understanding of GSCs.
The overall hypotheses were:
1. Cripto-1  is  present  in  GSCs  and  could  be  a  promising  target  to  direct
treatment in GBM (Manuscript I and II)
a. Objective: To characterize Cripto-1 in GBM
2. Patient-derived GBM cells represent a relevant model of GBM for use in
target  identification  and  molecular  understanding  of  GBM  plasticity
(Manuscript III and IV)
Four separate studies were conducted to address the overall objectives. The aims of
the studies were:
Manuscript  I:  To  investigate  the  subcellular  localization  of  cripto-1  in  an
overexpression  model  to  relate  its  localization  to  structures  associated  with  its
reported functions.
Manuscript II:  To evaluate  different  cripto-1 antibodies  for  use in  detection of
wildtype cripto-1, with the goal of investigating cripto-1 expression and localization
in GBM cells and tissue.
Manuscript III: To establish a relevant GBM model that recapitulates key GBM
features in vitro and in vivo.
Manuscript IV: To investigate the GBM cellular response to conventional GBM
treatments  in  vivo in  order  to  identify  significant  changes  in  surface  marker
expression associated to treatment resistant stem-like cells. 
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CHAPTER 3. SUMMARY OF FINDINGS
3.1. MANUSCRIPT I
Cripto-1 localizes to dynamic and shed filopodia associated with cellular
migration in glioblastoma cells
Johann Mar Gudbergsson, Meg Duroux
Manuscript published, European Journal of Cell Biology [169]
Background: Before investigating whether cripto-1 could be a beneficial target in
treating  GBM  tumors,  more  knowledge  on  the  expression  and  subcellular
localization of cripto-1 in GBM cells was desired.
Introduction: Cripto-1 is a membrane-anchored protein involved in cell migration
during embryonal development through the morphogenic TGF-β/Smad and Wnt/β-
catenin  pathways  and  has  been  found  overexpressed  in  several  types  of  cancer,
including GBM. The subcellular  localization and dynamics of  cripto-1 is  poorly
studied, which led us to investigate this further.
Main methods: Cripto-1 was stably overexpressed in U87MG cells. To evaluate the
localization  of  cripto-1,  immunocytochemistry  and  fluorescence-based  structured
illumination  microscopy  was  performed.  In  order  to  study  the  dynamics  of
membrane structures, live-cell spinning disk confocal imaging was performed using
CellMask Deep Red membrane stain. 
Results: We found that cripto-1, when overexpressed in U87MG cells, localized to
filopodia  structures  including  tunneling  nanotubes,  but  not  invadopodial  puncta.
Cripto-1 positive filopodia were shed from the trailing edge of the cells, which are
also called retraction fibers. Furthermore, cripto-1 was present in shorter filopodia
structures that resembled vesicles attached to the cell membrane via a lipid and actin
rich  string.  With live-cell  confocal  imaging  we found that  these  structures  were
highly dynamic membrane protrusions that could interact with retraction fibers.
Conclusion: We conclude that cripto-1 localized strongly to filopodia and retraction
fibers,  which indicates  that  the reported function of  cripto-1 harmonizes  with its




An evaluation of different Cripto‐1 antibodies and their variable results
Johann Mar Gudbergsson, Meg Duroux
Manuscript published, Journal of Cellular Biochemistry (2019) [170]
Background: Continuing our investigation of cripto-1 in GBM from Manuscript I,
we  wanted  to  detect  cripto-1  in  patient-derived  GBM  cells  under  wildtype
conditions (not overexpressed). 
Introduction:  Antibody-based  detection  of  cripto-1  is  widely  used  in  cripto-1
research.  High  plasma/serum  cripto-1  and  immunohistochemistry  detection  of
cripto-1 has been found to correlate with worse prognosis in several cancer studies.
In this study, we present a concise systematic review of cripto-1 antibodies and an
experimental evaluation of four widely used cripto-1 antibodies.
Main methods:  Primary  GBM cells  were  cultured in  serum-free  conditions and
seeded on geltrex matrix to study invasive cells. Immunocytochemistry was used to
detect  cripto-1  using  four  different  anti-cripto-1  antibodies.  All  four  cripto-1
antibodies were  tested for  binding to NTERA2 cells fixed with formaldehyde or
methanol.  A  systematic  literature  review  was  performed  on  cripto-1  antibodies.
Lastly,  sequence  alignment  (pBLAST)  and  3D-Match  structural  comparisons
(Phyre2) were used to compare preserved protein domains of cripto-1.
Results:  We found a  non-specific  binding  of  a  cripto-1  antibody to  the  geltrex
matrix onto which primary GBM cells were seeded, and no binding to cells. We thus
tested four different cripto-1 antibodies, and found that they all, in varying degree,
bound to geltrex. To further test how the antibodies bind, we bought the NTERA2
cell  line  as  it  is  generally  used  as  cripto-1  positive  control.  All  four  cripto-1
antibodies  bound differently  to NTERA2 cells,  with one antibody even  showing
intracellular  filament  staining.  We  then  did  a  systematic  review  of  cripto-1
antibodies in order to map the different epitopes or domains that the antibodies were
designed to bind on cripto-1. Here,  we found that many cripto-1 antibodies were
designed to bind to highly conserved domains within cripto-1, namely the EGF- and
CFC-domain.  Lastly,  we  highlight  some  possible  cross  reactants  from  similar
domains contained in other proteins.
Conclusion:  We conclude that  the different  cripto-1 antibodies investigated  here
present highly variable results and require more detailed characterization in future
cripto-1 studies.
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3.3. MANUSCRIPT III
A tumorsphere model of glioblastoma multiforme with intratumoral
heterogeneity for quantitative analysis of cellular migration and drug response
Johann Mar Gudbergsson, Serhii Kostrikov, Kasper Bendix Johnsen, Frederikke
Petrine Fliedner, Christian Brøgger Stolberg, Nanna Humle, Anders Elias Hansen,
Bjarne Winther Kristensen, Gunna Christiansen, Andreas Kjær, Thomas Lars
Andresen, Meg Duroux
Manuscript published, Experimental Cell Research (2019) [171]
Background: In order to identify GBM targets in future studies, we needed a well-
characterized primary GBM cell model for in vitro and in vivo studies.
Introduction: Due to the poor overall survival in GBM patients, novel treatments
need to be developed to target  the invasive cells. Often drug screening and drug
response assays are performed on generic GBM cell lines which could undermine
the translational potential.
Main  methods:  Patient-derived  primary  GBM  cells  T78  were  cultured  as
tumorspheres  in  serum-free  conditions.  Tumorsphere  migration  assay  was
performed by seeding single tumorsphere onto geltrex matrix.  For drug response
evaluation, extracellular vesicles and oxaliplatin were tested. Migration was tracked
using  phase-contrast  time-lapse  imaging  and  area  quantification.
Immunofluorescence imaging on cells was performed with a structured illumination
microscope and immunohistochemistry with a fluorescent slide scanner. 
Results:  Differential  intercellular  expression  of  GFAP and  Nestin  was  found  in
tumorspheres seeded onto geltrex with GFAP-  Nestin+ cells primarily located in the
migrating cells in the tumorsphere periphery. We showed that this expression pattern
was  also  present  in  vivo.  We furthermore  established  that  our geltrex  migration
assay with patient-derived GBM cells was suitable to test cancer growth inhibitors
and stimulators illustrated with oxaliplatin and extracellular vesicles, respectively. 
Conclusion:  The geltrex tumorsphere migration assay with patient-derived GBM
cells showed location-based intercellular heterogeneity and could be used for drug
response evaluation in vitro. 
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3.3.1. DIFFERENCE IN GBM TUMOR GROWTH BETWEEN U87MG AND 
PATIENT-DERIVED T78 CELLS
Prior to the studies conducted in Manuscript III, we performed a pilot study in order
to compare the growth curves of the widely used generic cell line U87MG and the
patient-derived T78 cells. GBM cells were implanted as described in Manuscript III,
and tumor growth was monitored with MRI. U87MG tumors grew to a mean size of
31 mm3 in 23 days compared to a mean size of around 10 mm3 in 49 days with T78
tumors  (Figure  3.1).  Although  growing  a  lot  slower  than  U87MG  tumors,  T78
tumors showed a steady growth with less inter-tumor size variance.
Figure 3.7. U87MG & T78 tumor growth curves. U87MG GBM cells (200.000 per mouse, n 
= 3) and patient-derived T78 GBM cells (100.000 or 200.000 per mouse, T78.1 and T78.2, 
respectively. n = 3) were implanted into NMRI nude mice and monitored with MRI as 
described in Gudbergsson et al. 2019 [171]. Data are presented with mean ± SD.
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3.4. MANUSCRIPT IV
Conventional treatment for glioblastoma reveals persistent CD44+
subpopulations
Johann Mar Gudbergsson, Esben Christensen, Serhii Kostrikov, Kasper Bendix
Johnsen, Torben Moos, Meg Duroux, Andreas Kjær, Thomas Lars Andresen
Manuscript submitted
Background: Expanding on the study presented in manuscript III, we wanted to use
the model to characterize drug response in vivo. 
Introduction:  In  GBM,  treatment  resistance  represents  a  tremendous  problem.
Understanding  how  GBM  cells  respond  to  conventional  GBM  treatments  could
reveal new potential targets for novel therapies. 
Main methods: Intracranial xenografts of patient-derived T78 cells were performed
in NMRI nude mice, which were monitored weekly with MRI for tumor growth.
Irradiation, temozolomide or combination treatments were administered once tumors
averaged 5 mm3.  Flow cytometry was performed on single cell  suspension from
dissociated  mouse  brains,  and  subsequently  analyzed  with  FlowSOM  cluster
analysis. Immunohistochemistry and fluorescence microscopy were performed for
qualitative analyses. TCGA patient analyses were done with the OncoLNC online
tool.
Results: Treatments significantly reduced tumors without eradicating them, leaving
behind GBM cells that could be analyzed with flow cytometry for the expression of
CD34,  CD44,  CD133  and  CXCR4.  Most  significantly,  an  approximate  8-fold
increase in CD44+ GBM cells was seen in all treatment groups. This was confirmed
by cluster analysis that showed a relative increase in several CD44+ subpopulations,
including  one  that  was  CD44+  CD133-  CXCR4-  CD34-.  Immunohistochemistry
results  cemented  these  findings  and  revealed  a  mouse-derived  CD44+ response
around GBM tumor cells. CD44+ and Nestin+ GBM cells were furthermore shown to
be invasive and residing in perivascular niches, and irradiated GBM cells displayed
increased tumor microtubes. Lastly, GBM and low-grade glioma patients with high
expression of CD44 had a decreased overall survival compared to patients with low
expression.
Conclusion:  We  show  here  that  CD44  is  involved  in  the  cellular  response  to
conventional  GBM  treatment  in  patient-derived  GBM  cells,  and  could  be  of




CHAPTER 4. GENERAL DISCUSSION
This discussion will focus on putting all the manuscripts in a coherent meta context,
and thus will each of the discussions from the studies not be repeated unless for
contextual  purposes.  Overall,  I  will  here  present  a  reflection  of  fundamental
concepts relating to GBM biology and the targeting of GSCs.
4.1. THE FUTURE OF CRIPTO-1: POTENTIAL AND PITFALLS
Cripto-1 has been shown to play an important role during embryonal development
and in malignant progression in several types of tumors. The attractive notion that
Cripto-1 is only expressed at low levels in the adult and seemingly highly expressed
in  tumors  makes  it  a  potential  target  for  treatment.  It  has  been  implicated  in
processes that are hallmarks for cancer stem or progenitor cells, perhaps acting in a
morphogen-like fashion as proposed during embryonal development. In Manuscript
I, we detailed the subcellular localization of Cripto-1 to filopodia structures and saw
it being shed in lipid-rich structures (shed filopodia or retraction fibers) and present
in  dynamic,  plasma  membrane-attached  filopodia  [169,172].  The  localization  to
filopodia structures  fits well  with Cripto-1 being a morphogen-associated protein
since filopodia are implicated in generating morphogen gradients. However, when
looking for wildtype Cripto-1 expression in primary GBM cells, we saw that four
different  Cripto-1 antibodies yielded different  results (Manuscript  II).  This raises
concerns since many studies that have discovered Cripto-1 in the different cancers
use  anti-Cripto-1  antibodies  to  reach  their  conclusions.  Only  two  studies  have
investigated and found Cripto-1 in GBM and are also using anti-Cripto-1 antibodies
to reach their conclusions [125,126]. Tysnes et al. use the polyclonal 600-401-997
from Rockland to investigate Cripto-1 as a prognostic biomarker in GBM  [125].
This antibody was a part of our evaluation in Manuscript II and yielded different
results from the other three antibodies evaluated. Pilgaard et al. use a few different
anti-Cripto-1  antibodies  for  the  different  methods  used  to  examine  Cripto-1
expression. For western blotting of wildtype U87 cells they used a goat anti-human
polyclonal  antibody from R&D Systems showing an intense Cripto-1 signal  just
below the 37 kDa mark [126]. We did anti-Cripto-1 western blots in Manuscript I
with the ABD13 antibody, showing no Cripto-1 binding to wildtype U87 cells. In
the Cripto-1 overexpressing U87 cells, we showed Cripto-1-positive bands around
the 25 kDa mark. This substantiates the concerns raised about Cripto-1 antibodies
and could call into question whether Cripto-1 is expressed in GBM.
So, how can we in Manuscript I then trust the results when the antibody used is
questioned in Manuscript II? The antibody used in Manuscript I (ABD13) does not
stain wildtype U87 cells in our hands but does so after transfection with a Cripto-1
plasmid. This was shown with western blotting and fluorescence microscopy using
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ABD13 and flow cytometry using FAB2772P anti-Cripto-1 antibodies. Instead of
using antibody-based protein detection, we could have investigated transcriptional
levels of Cripto-1 with qRT-PCR or  in situ-hybridization methods. For antibody-
independent protein detection, mass spectrometry could have been used. However,
to identify whether Cripto-1 is present in GSCs, it is necessary to know whether the
Cripto-1 expressing  cells  are  GSCs or  not,  and thus simultaneously needs  to  be
evaluated  for  the  presence  of  GSC  markers.  Furthermore,  to  investigate  the
anatomical  location  of  Cripto-1+  (i.e.  in  the  different  GSC  niches)  microscopy
techniques are required, in which the use of antibodies is desired.
To confidently investigate wildtype Cripto-1 protein expression in
GBM, better characterization of current Cripto-1 antibodies needs to be done and
new well-characterized monoclonal antibodies needs to be developed. After raising
the  concern  on  Cripto-1  antibodies  we  decided  not  to  put  more  work  into
investigating the potential of Cripto-1 as a target in GBM.
4.2. CD44 AS A POTENTIAL TARGET
In order to identify a new potential GSC target, we used our previously described
model (Manuscript  III)  and conducted a larger  in vivo study looking at  how the
GBM cells respond to TMZ, IR and TMZ+IR (Manuscript IV). In GBM, CD44 has
been  found  residing  in  several  GSC niches,  such  as  the  perivascular  and  peri-
necrotic niche [22,142,173]. CD44 was also found expressed in GSCs and abundant
expression  in  the  treatment  resistant  mesenchymal  GBM  cells  [16,147,174].  In
Manuscript IV, we observed an increase in CD44+ cell populations as a result of
treatment, and an increase in stromal mouse-derived CD44 was seen expressed in
and around the tumor indicating a reactive CD44 host-response to the tumor. Other
studies have also found upregulation of CD44 in response to irradiation treatment in
GBM models  [70]. Since CD44 expression seems to be upregulated in GSCs and
represents the most aggressive GBM cells, it  could be a potential target in GBM
treatment. Although CD44 has mostly been described in cancer settings, it has also
been implicated in embryo and tissue development (or morphogenesis)  [175–178].
In Manuscript I, we saw that CD44 co-localized with Cripto-1 in dynamic and shed
filopodia,  perhaps  indicating that  CD44 could be  involved in  some of  the same
processes as Cripto-1. The notion of CD44 being a morphogen-associated protein
only strengthens its potential as a possible target in GBM. As seen in Manuscript IV,
the added upregulation of CD44 in the stroma around tumors combined with high
expression  in  GSCs could further  increase  the directed  uptake  of  CD44-targeted
treatment  [179,180].  However,  CD44  is  a  highly  complex  protein  consisting  of
several isoforms that have different functions. In GBM, not much research has been
put into elucidating the expression of the different variants but one study found that
CD44v6 in particular regulates GSC growth [181]. This variant has also been found
to be expressed in CSCs in other tumor types, especially those of hematopoietic or
epithelial origin [182,183]. Targeting of CD44s and CD44v6 has been done in a few
40
CHAPTER 1. INTRODUCTION
studies in rodent pancreatic  cancer  models in vivo  which inhibited tumor growth
[184,185]. Side effects were, however, not evaluated. 
The expression of CD44 in various normal adult tissue throughout
the body, including the CNS, complicates its use as a target and requires rigorous
assessment of potential side effects [138,186]. If a functional inhibition of CD44 is
sought  to  be  achieved  through  targeting  of  CD44,  further  research  into  the
expression of CD44 variants in GBM could prove fundamental in order to minimize
side effects.  Otherwise,  targeting moieties  that  do not functionally interfere  with
CD44 function could be designed in order to circumvent this issue.
4.3. THE ENIGMA OF GSC TARGETING
One thing is to find a potential target and another to develop a suitable treatment
approach  that  will  effectively  reach  the  target,  especially  when  that  target  is
protected by the blood-brain barrier (BBB). Several different treatment approaches
exist including small molecule-based drugs, nanoparticle drug delivery vehicles such
as  liposomes  or  polymer  nanoparticles,  immunotherapies  such  as  antibodies  or
antibody fragments, or cell-based treatments such as vaccines or T cell therapies.
Being  in  the  brain,  GBM is  subjected  to  the  protective  BBB,  but  the  enhanced
permeability and retention (EPR) effect is present in the tumor bulk where tumor-
derived  vasculature  has  been  formed  [187].  During  surgical  resection,  however,
most  of  these  blood  vessels  (if  not  all)  are  removed  with  the  tumor  bulk  and
therefore also the tumor cells that are affected by the EPR. The tumor cells still
present in the brain in the invasive niche and potential small satellite tumors that
have not yet produced their own blood vessels, are most likely still protected by the
BBB [188]. This means that any future treatment targeting these cells needs to have
the ability to penetrate the BBB and reach the target cells located in the brain, which
so far has proven to be a difficult task [189]. Or, in order to bypass the intact BBB,
intrathecal administration could be done [190].  
When it comes to GSC niches, hypoxia is frequently mentioned as a
contributor to niche maintenance whether it being in the perinecrotic or perivascular
niche, and one can even imagine that hypoxia could play a role in the invasive niche
[174,191]. Thus, even i.v. injection of BBB-penetrable drugs might not effectively
reach the GSCs in hypoxic niches since the distance from a blood vessel could be
too far  to  rely  on diffusion of  the drug.  In  contrast,  intrathecal  delivery  of  IgG
antibodies  in  healthy  rats  showed  distribution  throughout  the  whole  brain  in
perivascular  spaces  of  all  vessel  types,  which  was  further  enhanced  if  co-
administered with hyperosmolar mannitol [190]. This could indicate that intrathecal
administration could deliver treatment to GSCs residing in the perivascular niche.
Since  neurons  and  white  matter  tracts  are  rarely  more  than  10-20  µm  from
capillaries (within the range of diffusion), even the invasive niche could be targeted
[192]. That is, if the diffusion properties in GBM tumors are the same as in the
healthy brain – which they are not. In GBM, an increased interstitial pressure and
peritumoral  edema is  often present  due  to  abnormal  vasculature  and insufficient
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lymphatic drainage  [193–196]. A failure to maintain pressure differences between
capillaries  and  brain  parenchyma  could  result  in  capillary  stasis  which  could
similarly affect the perivascular flow in those regions. In such cases, perivascular
diffusion could be limited, thus resulting in inefficient targeting of invasive GSCs.
Furthermore,  in  the  region  of  peritumoral  edema,  Engelhorn  et  al.  found  that
invasive GBM cells were residing herein [197]. If the peritumoral edema causes less
capillary exchange in the invasive region, a hypoxic state could be generated, further
contributing to the maintenance of stemness in invading GBM cells. The issues of
access to the invasive cells along with their abilities to adapt to treatment, makes it
immensely difficult to cure GBM [198–200].
4.4. ‘ALL MODELS ARE WRONG, BUT SOME ARE USEFUL’
To be  able to  further  our  understanding of  GBM tumor biology to progress  the
development of novel GBM treatments, clinically relevant model systems are key.
During the past decades, a vast improvement of cellular and xenograft GBM models
has taken place. The isolation of primary (patient-derived) GBM cells has gained
increased  attention  and  the  methods  of  propagating  the  cells  have  improved,
switching  to  either  serum-free  non-adherent  tumorsphere  culture  conditions  that
promote  stem-like  properties  or  subcutaneous  propagation  in  vivo.  Orthotopic
intracranial implantation of GBM cells has also seen an increased favoring among
researchers  compared  to  subcutaneous  GBM  tumors,  cementing  the
acknowledgement of the brain milieu in creating a more accurate recapitulation of
the clinical GBM picture. Here, I will discuss the GBM model used in our studies
and outline and discuss some conceptual challenges that preclinical GBM models
face.
In Manuscript III and IV we used the patient-derived GBM model T78, which has
previously been characterized in vitro and in vivo with respect to invasive properties
[201–203]. We have added to their characterization some depth in vitro by looking
into the intercellular heterogeneity based on cellular localization in a geltrex-based
tumorsphere migration assay [171]. Here, we showed that cells in the tumorsphere
periphery (actively migrating) lost GFAP expression and gained nestin expression.
Furthermore,  we  added  dimensions  to  the  treatment  side  of  the  tumorsphere
migration assay by demonstrating that migration could be increased and decreased
with  external  stimuli  [171].  In  vivo,  Munthe  et  al.  did  a  comprehensive
characterization of several stemness markers in several patient-derived GBM cells
and found that the peripheral GBM cells contained less stemness markers than in the
tumor core (presented as tumor area fraction in %) [202]. In our in vivo studies, we
saw  that  all  T78  cells  were  nestin+  when  stained  with  two  different  nestin
antibodies, but GFAP expression was lost in migrating cells in the periphery [171].
Munthe et al. did not co-stain with GFAP, hence we do not know whether the it
would be similar in their setup. In Manuscript IV, we expanded on the in vivo drug
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response  characterization  of  T78  and  analyzed  how  treatment  affected  GSC
subpopulations, illustrating that this model is suitable for such studies.
One major pitfall that generally applies to all tumor xenograft experiments is the
lack  of  or  altered  host  animal  adaptive  immune system,  a  necessity  for  human-
derived GBM tumors to form in other species. GBM tumors have long been known
to closely interact with the immune system and even harness or manipulate it to their
own benefit [204,205]. The immunodeficiency also means that a part of the survival
pressure is missing on the xenografted tumor cells which could impact the clinical
relevance  of  a  preclinical  study,  and  does  not  allow  studies  of  cancer
immunotherapies such as vaccines or cell-based treatments [206,207]. In Manuscript
III and IV we used NMRI nude mice which are convenient to work with for surgical
procedures  due to  the lack  of  fur.  However,  our  in vivo  model  animal  was also
immunodeficient  and  thus  subjected  to  the  general  pitfalls  mentioned  here.  To
circumvent  this,  researchers  have  come  up  with  generating  several  different
immunocompetent GBM tumor models, which include spontaneously or chemically
induced tumor formation and subsequent cell line generation, genetically engineered
models  (GEM)  and  humanized  mice  [160,208].  While  the  spontaneous  and
chemically induced cell lines are syngeneic, they are often poorly characterized with
respect to molecular GBM features  [50,168]. Mostly, the characterization is based
on histology to see if macro-anatomical similarities are present such as angiogenesis
and necrosis, making it difficult to directly translate the tumor response to treatment.
These models have, however,  been used in several preclinical immunotherapeutic
assessments  that  have led to  clinical  trials  [165].  GEMs are  produced through a
series of mutations in mice which then leads to formation of a syngeneic tumor, and
have been shown to be highly controllable and reproducible  [160,209]. Although
allowing for the study of single proteins or pathways in gliomagenesis, the models
could suffer from being too simple when evaluating a treatment response by only
representing few features of the tumor of origin. The murine immune system has
been heavily used as a tool to understand the human immune system, but due to
obvious species differences the two systems might not react in the same way to a
tumor or tumor treatment  [210–213]. To work around that, humanized mice have
been generated by engrafting human hematopoietic stem and progenitor cells into
severely  immunocompromised  mice  resulting  in  a  functioning  human  immune
system mixed with the remainder of the murine immune system (strain dependent)
[208]. Such models are, however,  highly expensive and time-consuming, limiting
their present use in research.
The most widely used mouse models are the immunocompromised mouse models,
for which the most widely used GBM cell lines for xenograft studies are U87MG
and  U251,  which  have  been  used  in  more  than  2000  and  1000  publications,
respectively [214]. These cells are notorious for being easy to culture, have a high
xenograft success rate and rapidly produce tumors in vivo. Generally, how complex
the xenograft tumor is and how well it resembles the clinical picture highly depends
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on the quality and integrity of the GBM tissue from which the cells are initially
extracted, the method of cell isolation and propagation (for example, adherent vs.
tumorsphere),  and  where  they  are  implanted  (orthotopic  vs.  heterotopic).  The
logistics and economy surrounding animal experiments might also impact the level
of tumor model quality, forcing low-budget laboratories  to use generic  cell  lines
instead of primary cells. Two success criteria for a tumor model are, in many cases,
how  fast  the  tumor  is  generated  and  the  inter-animal  success-rate  of  tumor
formation.  For  U87MG  and  U251  cells,  tumors  form  in  almost  all  inoculated
animals  and  grow to  a  “sufficient”  size  within two to three  weeks,  keeping  the
turnover  time for  experiments,  and  hence  also the  cost  of  the  experiments,  at  a
minimum [214]. To illustrate how large the difference can be between fast-growing
U87MG  xenograft  tumors  and  “slow-growing”  patient-derived  GBM  xenograft
tumors, we included results comparing U87MG tumor growth to the patient-derived
GBM tumor T78 (Figure 3.1). The immense difference sparked a few fundamental
questions: Does the time of growth in any way reflect the cellular complexity of the
tumors? We did not answer that question experimentally, but in Manuscript III we
saw that the T78 GBM tumors were not encapsulated such as is usually seen with
U87MG tumors, but were rather well integrated into the mouse brain [171,214,215].
The exponential growth rate in xenografts with generic cell lines such as U87MG
and U251 might imply that the majority of cells are actively proliferating. Is that
expected in human tumors as well, or could it insinuate intercellular homogeneity?
A study by Stensjøen et al. analyzed growth dynamics of 106 GBM patients using
MRI and found a mean daily tumor growth of 1.4 % and a mean doubling time of
tumor  volume  of  49.6  days  [216].  Comparing  these  numbers  to  our  preclinical
observations in Figure 3.3.
1, we find U87MG with a mean daily growth of 133 % and 18.5 % for T78. This
corresponds to a daily growth of U87MG being approximately 100-fold compared to
what Stensjøen et al. reported in human GBM patients, and T78 displays a 13-fold
difference  in  daily  growth  rate  [217].  A  difference  in  host-contributed  growth
dynamics between mouse and human is of course expected, but perhaps the fastest
and  most  consistently  growing  preclinical  GBM tumor  models  aren’t  the  better
choice when it comes to replicating the clinical picture, and thus might be less likely
to reflect a treatment response as would be seen in GBM patients. 
Intercellular heterogeneity is a clinical hallmark in GBM which should ideally be
replicated in preclinical models. If the cells used for xenografting are homogeneous
before  xenografting the tumor that  forms would most  likely be homogeneous  as
well, unless if using GBM stem- or progenitor cells whose cellular fate has not yet
been  locked  in.  When  it  comes  to  comparison  at  the  molecular  level,  GBM
xenograft  tumors  formed  from  freshly  isolated  patient-derived  GBM cells  were
shown to reflect the morphology and molecular characteristics of the original patient
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tumor, both with respect to the molecular subtype classification and expression of
Sox2 and EGFR  [218–220].  How the cells  are cultured  after  cell  isolation from
patient  specimens  has  been  shown  to  affect  the  intercellular  heterogeneity  and
success of integration into host tissue in the resulting xenograft. Hubert et al. were
the first to demonstrate that GBM-derived organoids cultured for approximately a
year  still  resembled the patient  tumor of  origin when xenografted and showed a
highly diffuse pattern compared to xenografts derived from a tumorsphere culture of
the same cells  [157]. Although the tumorsphere culture-derived xenograft in their
study  produces  a  highly  encapsulated  tumor,  we  showed  in  manuscript  III  that
diffuse xenograft  tumors could be produced from tumorsphere cultures that  have
been cultured for several passages [157,171].
4.4.1. MODELING THE ROOT OF RECURRENCE: THE ‘INVASIVE 
NICHE’
Throughout this thesis, many different characteristics of invasive GBM cells have
been  presented.  In  summary,  invasive GSCs are found in invasive niches in the
periphery of GBM tumors but are also found in perivascular niches due to vascular
co-option  (the  initial  step  in  the  neovascularization  cascade)  being  an  invasive
process.  In  order  to  invade  healthy  brain  parenchyma,  the  GSCs  dynamically
regulate  different  membrane protrusions (such as  lamellipodia  and filopodia)  for
anchoring to ECM (haptotaxis),  manipulating local  healthy/tumor-associated cells
via  tunneling  nanotubes,  tumor  microtubes  and  filopodia-dependent  morphogen
secretion, and for degradation of ECM via invadopodia. On a molecular level, the
invasive  GSCs  often  express  a  mesenchymal  phenotype  characterized  by
mesenchymal markers such as CD44, CD109, Notch1 and CXCL12 but have also
been shown to display proneural phenotypic markers such as Nestin and CD133, and
oligodendrocytic markers such as Olig2. General stemness markers such as Sox2,
Oct4 and L1CAM have also been described as expressed in invading GSC [13]. The
regulation of the GSCs has often been attributed to the local oxygen concentration
where  hypoxia  serves  as  a  main  driver  of  stemness  and  invasion  through  HIF
proteins.  Being highly plastic cells,  GSCs are in general  regulated by their local
environment which also includes responding to treatment, in which a mesenchymal
and invasive phenotype is induced rendering the GSCs more resistant to treatment.
Much research has been put into understanding the invasive cells of
GBM that drive its recurrence after heavy first-line treatments, but most of what is
known about  these  cells  stems from cultured cells  or  animal  experiments  [196].
Maximum safe resection surgery of GBM tumors is generally done with MR-based
guidance  using  gadolinium  as  a  contrast  or  by  using  5-ala  fluorescence-guided
surgery [221]. These surgery techniques have been shown to not be sensitive enough
to detect invasive GBM cells, hence the universal recurrence of the tumor [222]. The
only  way  to  characterize  these  invasive  GBM cells  would  be  to  examine  post-
mortem brains from GBM patients. Such studies exist, but only one study using IHC
to characterize the invasive cells could be found (with the applied search terms).
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Peng et al. examined two post-mortem brains from GBM patients and found that the
invasive tumor regions had more CD133 and Sox2-positive cells than other parts of
the tumors  [223]. With such scarce knowledge of how the invasive cells look at a
molecular level in human patients, it might be difficult to translate findings from
preclinical  studies. Although difficult and expensive,  it might be the only way to
evaluate the relevance of preclinical GBM models with respect to GSC invasion.
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CHAPTER 1. INTRODUCTION
CHAPTER 5. CONCLUDING REMARKS 
AND FUTURE PERSPECTIVES
GBM treatment has seen little progression in the past many years due to its delicate
location,  invasive  nature  and  heterogenic  composition,  unavoidably  resulting  in
tumor regrowth. The blood-brain barrier constitutes a significant obstacle in treating
GBM tumors,  shielding invasive GBM cells from the treatment.  In this thesis,  a
search for potential targets on the surface of hard-to-reach GSCs has been presented
in four studies in order to characterize the cells and find ways to direct treatment. 
Cripto-1 was hypothesized to be a potential target on GSCs due to its stem cell-
associated nature in health and cancer stem cell association in several different types
of cancer. We show for the first time a subcellular mapping of cripto-1 in cripto-1
overexpressed U87MG cells and find it highly enriched in filopodia structures, both
static/shed  filopodia  and  highly  dynamic  membrane-anchored  filopodia.  These
findings support  the role of  cripto-1 in  cellular  migration.  However,  in  order  to
specifically detect cripto-1 in GBM tumors or GSCs, cripto-1 antibodies need better
characterization  to  avoid  potential  false-positive  detection.  Production  of  highly
specific monoclonal antibodies designed to bind outside of the signal peptide, EGF
and CFC domains could facilitate proper detection of cripto-1 in future studies, both
as a biomarker and to study wildtype cripto-1 biology.
To enable  detection  of  relevant  surface  targets  on  GSCs a  model  of  GBM was
developed  and  characterized  in  vitro  and  in  vivo.  Here,  we  found  that  GBM
characteristics  seen  in  vivo  were  similarly recapitulated  in  in  vitro  tumorspheres
seeded on complex ECM such as geltrex. Expanding on this model with a large in
vivo study, we found that the cellular composition of the GBM tumor changed in the
mice  that  received  conventional  GBM  treatment.  Especially  one  protein  was
particularly upregulated, namely CD44, which could potentially serve as a target in
directed GBM treatment in the future. 
In  order  to  improve  GBM  treatment  more  fundamental  research  into  the  basic
biology of GBM is needed, with emphasis on the invading GBM cells that are not
affected by surgery and are more resistant to current treatment.  This would require
more high-resolution work, such as multi-color flow cytometry as we have presented
here,  on  patient  biopsies  and  surgical  specimen.  A  crucial  step  towards
understanding the invasive GBM cells, and how to reach them, is to analyze post-
mortem brains with immunohistochemistry techniques.
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